Pharmaceutical Technology on MSN11h
Leveragen and Moonlight Bio unite for T-cell therapy development
Leveragen has announced a strategic partnership with Moonlight Bio, targeting the development of T-cell therapies for ...
ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that Ameet Mallik, Chief Executive Officer, will ...
BioPharma Dive18h
Enhertu, with new OK, set to supplant chemo in HER2-low breast cancer
The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...
Hosted on MSN23h
FDA expands Enhertu approval to include HER2-ultralow breast cancer patients
Enhertu first secured approval in 2019 for patients with high levels of HER2, a protein that promotes cancer cell growth. In ...
The American Journal of Managed Care7h
Oncology R&D Will Follow Divergent Paths, Experts Say at JPM Event
A panel discussion during the JPMorgan conference earlier this month examined where oncology drug development is headed, driven in part by advances in diagnostic testing.
Roche Emerging From Difficult Covid Comparisons With Solid Pharma and Diagnostics Prospects
We think Roche's drug portfolio and industry-leading diagnostics conspire to create maintainable competitive advantages. As the market leader in both biotech and diagnostics, this Swiss healthcare ...
FierceBiotech14h
Roche drops HER2 bispecific, Xencor-partnered cytokine from early-phase pipeline
Roche has given two early-phase bispecifics the heave-ho, ending work on a HER2xCD3 prospect and an IL-15 candidate it picked up from Xencor. | Roche has given two early-phase bispecifics the heave-ho ...